Healthcare technology company Lifespot Health has appointed two cannabinoid specialists as non-executive board directors to help execute its strategy of delivering medication systems and therapies to market.
Dr Andrew Saich was European medical director for Intercept Pharmaceuticals when the company was expanding into 13 countries across Europe and, in 2016, he created and led GW Pharmaceuticals International Medical in preparation for the launch of Epidyolex for the treatment of rare and debilitating drug-resistant epilepsies.
Join the Cannabiz revolution
Want to stay ahead of the cannabis curve with the latest local and international news, analysis and intelligence and access to Australia's legal cannabis industry?
This article is included with our Premium subscription.